Circulating PD-1⁺ effector memory T cells predict anti-PD-1 efficacy in advanced gastric cancer.

ABSTRACT:

Background

Although standard chemotherapy combined with immunotherapy represented by programmed cell death -1(PD-1) blockade shows promise as a treatment approach for gastric cancer (GC), the drug response rates remain low. Identifying reliable biomarkers to predict patient response is urgently needed.

Methods

We collected baseline (before receiving PD-1 inhibitors) peripheral blood samples from advanced GC patients (n=54) who underwent PD-1 inhibitors and platinum drugs from January 2022 to December 2023 and investigated PD-1 expression on effector memory T (TEM) between responders and non-responders according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) guidelines by low-dose computed tomography scan evaluation. Univariate and multivariate analyses were app

SUBMITTER: Wang K 

PROVIDER: S-EPMC12727954 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature